Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Gaush MeditechFRA:F7Y +0.93%61 Receivables Turnover is 4.35 as of Dec. 2025. GuruFocus rates FRA:F7Y with a GF Score™ of 61/100 and a GF Value™ of €1.37 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 811 Medical Devices & Instruments companies, Gaush Meditech ranks better than 81.13% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Gaush Meditech's Revenue for the
six
months ended in Dec. 2025 was €88.2 Mil. Gaush Meditech's average Accounts Receivable for the
six
months ended in Dec. 2025 was €20.3 Mil.
Hence, Gaush Meditech's Receivables Turnover for the
six
months ended in Dec. 2025 was 4.35.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Gaush Meditech Receivables Turnover Related Terms
Gaush Meditech Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Gaush Meditech's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:F7Y vs ABT, SYK, MDT: Receivables Turnover Comparison
For the Medical Devices subindustry, Gaush Meditech's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gaush Meditech Receivables Turnover vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Gaush Meditech's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Gaush Meditech's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gaush Meditech (FRA:F7Y) has a Receivables Turnover of 4.35 as of Dec. 2025. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Gaush Meditech and its competitors. According to the industry distribution chart, Gaush Meditech ranks #153 out of 811 companies in the Medical Devices & Instruments industry, placing it in the top 18.9%.
Is Gaush Meditech's Receivables Turnover too high?
Gaush Meditech's current Receivables Turnover is 4.35. The Medical Devices & Instruments industry median Receivables Turnover is 5.51. Gaush Meditech's value of 4.35 is 21.1% below this industry median. Based on the distribution chart, Gaush Meditech ranks #153 out of 811 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Gaush Meditech has a GF Score™ of 61/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Gaush Meditech's Receivables Turnover compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Gaush Meditech ranks #153 out of 811 companies for Receivables Turnover. This places Gaush Meditech in the top 19% of its industry — outperforming the majority of peers. The industry median Receivables Turnover is 5.51. Gaush Meditech's value of 4.35 is 21.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Medical Devices & Instruments company?
The median Receivables Turnover among Medical Devices & Instruments companies is 5.51, based on 811 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Gaush Meditech's current Receivables Turnover of 4.35 is 21.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Gaush Meditech and its competitors. For the Medical Devices & Instruments industry, the median Receivables Turnover is 5.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gaush Meditech's current Receivables Turnover is 4.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gaush Meditech stock overvalued right now?
Based on GuruFocus' analysis, Gaush Meditech (FRA:F7Y) is currently considered Possible Value Trap. The stock's GF Value™ is €1.37, compared to a current price of €0.54 — trading 60.6% below its estimated fair value. The current Receivables Turnover is 4.35 and 21.1% below the Medical Devices & Instruments industry median of 5.51. Gaush Meditech's overall GF Score™ is 61/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Gaush Meditech (FRA:F7Y), the current Receivables Turnover is 4.35 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gaush Meditech (FRA:F7Y) Overvalued in 2026?
Based on GuruFocus' analysis, Gaush Meditech stock appears to be undervalued.
The current stock price of €0.54 is trading 60.6% below its estimated GF Value™ of €1.37.
GuruFocus considers Gaush Meditech to be Possible Value Trap.
Key valuation signals for FRA:F7Y:
Receivables Turnover: 4.35
GF Value™: €1.37 vs. price of €0.54 (60.6% below fair value)
Industry Position: 21.1% below the Medical Devices & Instruments median (#153 of 811)
No single metric tells the full story. See the FRA:F7Y stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gaush Meditech Ltd is a provider of a broad spectrum of manufacture and sale ophthalmic medical devices and provision of technical services. The segments of the company include Proprietary products segment that derives maximum revenue, develops and produces surgical equipment and related supporting software, intra-optical lens, ophthalmic disease diagnosis and treatment equipment and related supporting consumables independently; Distribution products segment sells multi-function diagnostic equipment, ocular fundus diagnosis, surgical and treatment equipment and related supporting consumables produced by ophthalmic medical equipment manufacturers; Technical services segment provides warranty services, maintenance services and other related consumables; and Others segment.
61GF Score
Get the complete analysis for FRA:F7Y
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:F7Y has been successfully added to your 
